ES2862950T3 - Anticuerpos anti-CD4 modificados con glicanos para la prevención y terapia del VIH - Google Patents

Anticuerpos anti-CD4 modificados con glicanos para la prevención y terapia del VIH Download PDF

Info

Publication number
ES2862950T3
ES2862950T3 ES13866337T ES13866337T ES2862950T3 ES 2862950 T3 ES2862950 T3 ES 2862950T3 ES 13866337 T ES13866337 T ES 13866337T ES 13866337 T ES13866337 T ES 13866337T ES 2862950 T3 ES2862950 T3 ES 2862950T3
Authority
ES
Spain
Prior art keywords
antibody
ibalizumab
hiv
modified
glycan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13866337T
Other languages
English (en)
Spanish (es)
Inventor
Ruijiang Song
David Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Application granted granted Critical
Publication of ES2862950T3 publication Critical patent/ES2862950T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES13866337T 2012-12-18 2013-12-18 Anticuerpos anti-CD4 modificados con glicanos para la prevención y terapia del VIH Active ES2862950T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261738777P 2012-12-18 2012-12-18
US201361864942P 2013-08-12 2013-08-12
PCT/US2013/076051 WO2014100139A1 (en) 2012-12-18 2013-12-18 Glycan-modified anti-cd4 antibodies for hiv prevention and therapy

Publications (1)

Publication Number Publication Date
ES2862950T3 true ES2862950T3 (es) 2021-10-08

Family

ID=50979141

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13866337T Active ES2862950T3 (es) 2012-12-18 2013-12-18 Anticuerpos anti-CD4 modificados con glicanos para la prevención y terapia del VIH

Country Status (7)

Country Link
US (1) US9790276B2 (enExample)
EP (1) EP2934589B1 (enExample)
JP (1) JP6408487B2 (enExample)
CN (1) CN105228650B (enExample)
ES (1) ES2862950T3 (enExample)
TW (1) TWI630215B (enExample)
WO (1) WO2014100139A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9587022B2 (en) 2012-12-18 2017-03-07 The Rockefeller University Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
AU2014360760B2 (en) 2013-12-02 2019-12-12 The Trustees Of Columbia University In The City Of New York Improved HIV-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture
EP3261651B1 (en) * 2015-02-27 2022-05-04 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
JP6936221B2 (ja) * 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
US11472889B2 (en) 2017-10-14 2022-10-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
CN114269778B (zh) * 2019-08-19 2024-10-01 洛克菲勒大学 具改良药物动力学的经酸碱度依赖性抗原结合活性工程化的抗人类免疫缺乏病毒抗体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU662891B2 (en) 1990-11-27 1995-09-21 Biogen Idec Ma Inc. Anti CD-4 antibodies blocking HIV-induced syncytia
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
ATE440959T1 (de) 2000-06-28 2009-09-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
EP1888637A2 (en) * 2005-05-19 2008-02-20 Amgen Inc. Compositions and methods for increasing the stability of antibodies
CA2632828C (en) * 2005-12-12 2012-07-10 F. Hoffmann-La Roche Ag Antibodies against amyloid beta with glycosylation in the variable region
WO2008134046A1 (en) 2007-04-27 2008-11-06 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
US9156912B2 (en) * 2008-12-12 2015-10-13 The University Of Tokyo Immunological reconstitution promoter or prophylactic agent for infections each of which maintains graft-versus-tumor effect
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
CN103282385A (zh) * 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
US9587022B2 (en) 2012-12-18 2017-03-07 The Rockefeller University Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity

Also Published As

Publication number Publication date
US9790276B2 (en) 2017-10-17
US20160362493A9 (en) 2016-12-15
JP6408487B2 (ja) 2018-10-24
EP2934589B1 (en) 2021-01-13
CN105228650B (zh) 2018-11-16
WO2014100139A1 (en) 2014-06-26
CN105228650A (zh) 2016-01-06
EP2934589A1 (en) 2015-10-28
TWI630215B (zh) 2018-07-21
US20150166662A1 (en) 2015-06-18
TW201441258A (zh) 2014-11-01
EP2934589A4 (en) 2016-08-10
JP2016503059A (ja) 2016-02-01

Similar Documents

Publication Publication Date Title
US9587022B2 (en) Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
US8637024B2 (en) Fusion antibodies for HIV therapy
TWI847020B (zh) 抗冠狀病毒抗體及使用方法
CA2888659C (en) Broadly-neutralizing anti-hiv antibodies
Padte et al. Engineering multi-specific antibodies against HIV-1
US10654943B2 (en) Tri-specific antibodies for HIV therapy
JP5763344B2 (ja) Ｃ型肝炎ウイルス抗体
JP6408487B2 (ja) Ｈｉｖの防止および療法のためのグリカン修飾された抗ｃｄ４抗体
Song et al. Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1–neutralizing activity
US20160145321A1 (en) Human antibodies binding to rsv g protein
US20230242624A1 (en) HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
CN114751987B (zh) 一种中和冠状病毒的多特异性抗体
US20250154231A1 (en) Antibodies capable of binding to the spike protein of cononavirus sars-cov-2
Gong et al. Candidate antibody-based therapeutics against HIV-1
CN114751988B (zh) 中和冠状病毒的多特异性抗体
CN114751986B (zh) 中和新冠病毒的多特异性抗体
US12012451B2 (en) Engineering pH-dependent antigen binding activity into anti-HIV antibodies with improved pharmacokinetics
US20240409617A1 (en) Multispecific coronavirus antibodies
US9938325B2 (en) HIV-1 antigens with discrete conformational forms in the V1/V2 domain and methods of use thereof
HK40115212A (zh) 广泛中和性抗hiv抗体